Newswise — (NEW YORK – November 19) –– Many of the nation’s top liver cancer experts will discuss advances in treatment of liver cancer at the International Liver Cancer Association (ILCA) School of Liver Cancer symposium hosted by Icahn School of Medicine at Mount Sinai December 11-12 at The New York Academy of Medicine. Steven Burakoff, MD, Director of the Tisch Cancer Institute at Mount Sinai will deliver the keynote address.
The special two-day symposium will feature lectures by physicians and researchers covering advancements in the understanding of the mechanisms that cause liver cancer, new clinical trials, and the standard of care.
Josep M. Llovet, MD, Professor of Medicine, Icahn School of Medicine, Director, Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute at Mount Sinai, will host the event. Dr. Llovet is a leading expert in the clinical management of Hepatocellular Carcinoma (HCC), and genomic predictors for this disease. Scott Friedman, MD, Chief, Division of Liver Diseases, Professor and Dean of Therapeutic Discovery, and Myron Schwartz, MD, Professor of Surgery, Director of Liver Surgery, Icahn School of Medicine at Mount Sinai, are co-directors of this event.
“The purpose of the event is to bring together an international body to learn from one another, share experiences at the bedside, as well as establish research collaborations,” said Dr. Llovet. “This is the first meeting ever organized globally, and we are pleased to have been chosen for such event due to our international recognition as a leading center in liver cancer research. We welcome researchers and graduate students to participate.” The goal of the ILCA School of Liver Cancer is to promote basic, clinical, translational, multi-disciplinary and multi-national liver cancer research, including the development of clinical trials; to encourages and facilitates scientific exchange and dissemination of knowledge; to educate physicians, scientists, allied healthcare professionals and the general public at large; and educate international and national health authorities on the diagnosis, prevention and management of liver cancer.
To learn more about the 2014 ILCA School of Liver Cancer Symposium, please visit: http://www.ilca-online.org/.
About the Mount Sinai Health SystemThe Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven member hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community‐based facilities to tertiary and quaternary care.
The System includes approximately 6,600 primary and specialty care physicians, 12‐minority‐owned free‐standing ambulatory surgery centers, over 45 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island, as well as 31 affiliated community health centers. Physicians are affiliated with the Icahn School of Medicine at Mount Sinai, which is ranked among the top 20 medical schools both in National Institutes of Health funding and by U.S. News & World Report.
For more information, visit http://www.mountsinai.org, or find Mount Sinai on Facebook, Twitter and YouTube.
About the International Liver Cancer Association The International Liver Cancer Association (ILCA) is the only international organization devoted exclusively to liver cancer research for experts from all related disciplines. The mission of the organization is to aspires towards advancing research in the pathogenesis, prevention, and treatment of liver cancer and does so by promoting novel pathogenic, diagnostic and therapeutic interventions for liver cancer by taking a transversal approach to research and bringing together scientists, physicians and allied professionals from all interrelated fields.
# # #
RSS